Heart failure patients enrolled in Humana Medicare Advantage plans can now have Barostim, a small implantable nerve stimulator, paid for by their insurer. The coverage policy took effect on 1 May 2026 and makes Humana the first major US payer to issue a formal Medicare Advantage coverage policy for the device. Barostim sits in the chest like a pacemaker, with a thin lead running to a nerve cluster in the carotid artery in the neck. It sends electrical pulses to those nerves, calming an over-driven autonomic nervous system and reducing the workload on a failing heart. For CVRx, the Minneapolis company that makes Barostim, this is the fourth reimbursement or trial milestone landed in 2026.

Four milestones, five months

The Humana policy is the fourth Barostim milestone CVRx has logged this year. On 1 January 2026, the American Medical Association moved the Barostim procedure into its Category I billing tier, where established procedures sit and hospitals can bill routinely. Barostim had previously been classified Category III, the experimental tier. In the same month, the Centers for Medicare & Medicaid Services agreed to cover the routine medical care of patients enrolled in CVRx’s BENEFIT-HF expanded-population trial, removing a paperwork-and-funding barrier that has historically slowed device-trial enrolment in the US. CVRx enrolled the first BENEFIT-HF patient on 4 May 2026 at North Central Heart in Sioux Falls, South Dakota. Ten days later, Humana’s coverage policy landed.

The Category I CPT switch is already moving the numbers. CVRx’s 30-day Medicare Advantage prior-authorization approval rate rose from 31% in 2024 to 44% in 2025 to 50% in the first two months of 2026. Humana coverage now removes payer-specific policy uncertainty for the patients in its Medicare Advantage book.

What BENEFIT-HF is testing

BENEFIT-HF is one of the largest cardiac device trials ever attempted in heart failure. It is a randomised controlled trial that will enrol 2,500 patients at approximately 150 hospitals in the United States and Germany. Researchers will compare patients who receive Barostim alongside guideline-directed medical therapy against patients who receive medical therapy alone, tracking whether Barostim reduces a composite of all-cause mortality and heart-failure hospitalisations through 2032.

The trial expands eligibility to patients with left ventricular ejection fraction below 50%, substantially broader than Barostim’s current label (NYHA Class III, LVEF ≤35%, NT-proBNP <1600 pg/mL). If BENEFIT-HF reads out positively, CVRx expects the indicated patient population to expand by roughly three times.

CVRx is funding the trial. CMS reimburses the routine medical care of trial enrollees. Humana now adds private-payer coverage in parallel. The clinical work is paid for, and the commercial scaffolding is tightening underneath it.

Where Barostim fits in the bioelectronic shift

Barostim is the only FDA-approved baroreflex neuromodulation therapy for heart failure. The device works by talking to the autonomic nervous system rather than stimulating the heart muscle directly. That places it alongside a small cluster of implantable devices that read or modulate the body’s own electrical signalling rather than overriding it.

The category consolidated noticeably across 2026, covered in Inside BCI’s 5 May commercial-inflection piece: closed-loop spinal cord stimulation (Medtronic Inceptiv), adaptive deep brain stimulation for Parkinson’s (Medtronic BrainSense), responsive neurostimulation for epilepsy (NeuroPace RNS), and now autonomic interfaces with Medicare Advantage coverage.

Inside BCI’s 8 May piece covered the CMS WISeR rule moving Inspire Medical onto prior authorization while leaving NeuroPace RNS untouched. The CVRx win is the same pattern from the other direction. Where CMS used WISeR to slow lower-acuity indications, payers are moving early to cover higher-acuity autonomic therapies whose clinical case is locked. The category is differentiating, not consolidating.

What to watch

The next visible signals are coverage moves by the other top Medicare Advantage payers. UnitedHealthcare, CVS Health (Aetna), and Elevance Health (Anthem) all run Medicare Advantage at scale and have not yet issued public coverage policies for Barostim. Traditional Medicare Local Coverage Determinations from the regional Medicare Administrative Contractors are the parallel path. Any movement on either over the next twelve months will set the speed at which the broader payer environment converges around the same coverage logic. The earliest BENEFIT-HF interim readouts are years away. The scaffolding around the device is hardening regardless.

Sources

• CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy (GlobeNewswire, 14 May 2026)
• CVRx earns Humana Medicare Advantage win for Barostim (MassDevice)
• CVRx Announces First Patient Enrollment in BENEFIT-HF (GlobeNewswire, 4 May 2026)
• CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy (CVRx IR)
• Medicare Advantage enrolment decelerates as insurers shed members for 2026 (Healthcare Dive)